VERAXA Biotech AG (NASDAQ: VRXA) announced that its shareholders overwhelmingly approved all proposals presented at the company's Extraordinary General Meeting. According to the press release, more than 99.94% of votes cast were in favor, with 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.
The company stated that the enhanced corporate and financing framework is designed to support its long-term growth strategy. This framework provides greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management noted that the vote reflects strong shareholder support for VERAXA's strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
VERAXA is focused on discovering and developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's pipeline is driven by transformative technologies and quality-by-design principles, rapidly advancing its ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
For more details, the full press release can be accessed at https://ibn.fm/qfL87. Additional information and updates about VERAXA are available in the company's newsroom at http://ibn.fm/VRXA.
